SCYL1

Across TCGA pan-cancer cohorts, SCYL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SCYL1 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SCYL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SCYL1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where SCYL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	1.000	0.291	.001	35	view →
CCRCC	OS	Median	IV	0.123	0.785	.009	23	view →
GBM	OS	Quartile	All	0.334	0.662	<.001	14	view →
LSCC	DFS	Median	III,IV	0.456	0.864	.011	7	view →
PDAC	DFS	Median	III,IV	0.203	0.507	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SCYL1–HNSC (DFS)

Open the HNSC breakdown →